Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer

Xiangxun, Chen; Zhou, Mengxi; Fan, Wei; Yang, Mingwei; Yang, Lin

doi:10.2147/dddt.s282777

Cited by 5 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kian's group tested this salt against breast cancer and detected apoptosis and cell cycle arrest with possible implication of p53 [125]. Moreover, Chen et al [126] reported a study related to the synergistic effect between cisplatin and sodium cantharidinate for cervical cancer treatment. On the other hand, the acid form (cantharidic acid) was able to induce apoptosis through p-38 upregulation [127].…”

Section: Oxanorbornene Derivativesmentioning

confidence: 99%

“…. Norcantharidin , cantharidin [119][120][121][122][123][124][125][126][127][128][129][130][131], and related molecules.…”

Section: Oxanorbornene Derivativesmentioning

confidence: 99%

“…Other relevant derivatives are the cantharidin-sulfanil-Figure 9. Norcantharidin , cantharidin [119][120][121][122][123][124][125][126][127][128][129][130][131], and related molecules.…”

Section: Oxanorbornene Derivativesmentioning

confidence: 99%

See 2 more Smart Citations

Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments

et al. 2022

View full text Add to dashboard Cite

The norbornene scaffold has arisen as a promising structure in medicinal chemistry due to its possible therapeutic application in cancer treatment. The development of norbornene-based derivatives as potential chemotherapeutic agents is attracting significant attention. Here, we report an unprecedented review on the recent advances of investigations into the antitumoral efficacy of different compounds, including the abovementioned bicyclic scaffold in their structure, in combination with chemotherapeutic agents or forming metal complexes. The impact that structural modifications to these bicyclic compounds have on the antitumoral properties and the mechanisms by which these norbornene derivatives act are discussed in this review. In addition, the use of norbornene, and its related compounds, encapsulation in nanosystems for its use in cancer therapies is here detailed.

show abstract

Section: Oxanorbornene Derivativesmentioning

confidence: 99%

“…. Norcantharidin , cantharidin [119][120][121][122][123][124][125][126][127][128][129][130][131], and related molecules.…”

Section: Oxanorbornene Derivativesmentioning

confidence: 99%

See 1 more Smart Citation

Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It has demonstrated a good therapeutic effect on malignant tumors, especially in advanced cancers, including gastric cancer [ 14 ], liver cancer [ 15 , 16 ], breast cancer [ 17 ], lung cancer [ 18 ], oral squamous cell carcinomas [ 19 ], etc. [ 20 , 21 ]. Its pertinent anticancer mechanisms on cancerous cells include protein phosphatase 1 and protein phosphatase 2A inhibition, apoptosis induction, and protein synthesis alteration [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma

Wang

Ning

et al. 2022

Molecules

View full text Add to dashboard Cite

Cantharidin (CTD) is the major component of anticancer drugs obtained from Mylabris Cichorii and has a good inhibitory effect on several cancers, including hepatocellular carcinoma (HCC) and breast cancer. However, due to its toxicity, oral administration can cause various adverse reactions, limiting its clinical application. The aim of this work was to design glycyrrhetinic acid (GA)- and/or folate (FA)-modified solid lipid nanoparticles (SLNs) for the encapsulation of CTD to target HCC. Four CTD-loaded SLNs (cantharidin solid lipid nanoparticles (CSLNs), glycyrrhetinic acid-modified cantharidin solid lipid nanoparticles (GA-CSLNs), folate-modified cantharidin solid lipid nanoparticles (FA-CSLNs), and glycyrrhetinic acid and folate-modified cantharidin solid lipid nanoparticles (GA-FA-CSLNs)) were prepared by the emulsion ultrasonic dispersion method, and their physicochemical parameters were determined (particle size and distribution, morphology, zeta-potential, entrapment efficiency, drug loading, and hemolysis). Additionally, the antitumor activities of the four SLNs were evaluated comprehensively by tests for cytotoxicity, cell migration, cell cycle, apoptosis, cellular uptake, competition suppression assay, and in vivo tumor suppression assay. Four SLNs showed spherical shapes and mean diameters in the range of 75–110 nm with size dispersion (PDI) within the range of 0.19–0.50 and zeta-potential approximately –10 mV. The entrapment efficiency of CTD in SLNs was higher than 95% for all tested formulations, and no hemolysis was observed. Compared to GA-CSLNs or CSLNs, GA-FA-CSLNs and FA-CSLNs showed stronger cytotoxicity on hepatocellular carcinoma cells (HepG2), and the cytotoxicity of GA-FA-CSLNs on hepatocyte cells (L-02) was remarkably reduced compared with other formulations. GA-FA-CSLNs and FA-CSLNs also increased the inhibition of HepG2 cell migration, and FA-CSLNs had the highest apoptosis rate. The cell cycle results indicated that HepG2 cells were arrested mainly in the S phase and G2/M phase. Analysis of competition inhibition experiments showed that GA and FA ligands had targeted effects on HepG2 cells. The in vivo tumor inhibition experiment showed that GA-FA-CSLNs and FA-CSLNs had excellent tumor inhibition ability—their tumor inhibition rates were 96.46% and 89.92%, respectively. Our results indicate that GA-FA-CSLNs and FA-CSLNs have a promising future in the therapeutic intervention of HCC.

show abstract

“…Clinical studies have shown that SCA combined with hepatic artery perfusion have achieved significant efficacy in the treatment of patients with hepatocellular carcinoma (HCC) (16), and SCA injection was also approved by the China Food and Drug Administration in 2013 for HCC (17). Recent clinical observations have found that SCA combined with chemotherapy exerted a significant synergistic effect in the treatment of esophageal, gastric, pancreatic and cervical cancer, osteosarcoma and other solid tumors, without increasing the incidence of adverse events (18)(19)(20)(21). In 2014, Wang et al (22) conducted a clinical study found that the clinical efficacy of SCA combined with GP regimen in the treatment of advanced NSCLC was better than the conventional GP regimen.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

Deng

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Second-line treatment options for advanced/metastatic non-small cell lung cancer (NSCLC) patients are limited. We aimed to evaluate the efficacy and safety of docetaxel/sodium cantharidinate combination vs. either agent alone as second-line treatment for advanced/metastatic NSCLC patients with wild-type or unknown EGFR status. A randomized, open-label, phase III study was performed at 12 institutions. Patients with failure of first-line platinum regimens were randomized to receive either single-agent sodium cantharivsdinate (SCA) or single-agent docetaxel (DOX) or docetaxel/sodium cantharidinate combination (CON). The primary endpoints were centrally confirmed progression-free survival (PFS) and overall survival (OS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), quality of life (QoL) and toxicity. A total of 148 patients were enrolled in our study between October 2016 and March 2020. After a median follow-up time of 8.02 months, no significant difference was observed among the three groups in ORR (SCA vs. DOX vs. CON: 6.00% vs. 8.33% vs. 10.00%, respectively; p=0.814) and DCR (74.00% vs. 52.00% vs. 62.50%, respectively; p=0.080). In additional, the mOS was significantly higher in the CON group, compared with the single-agent groups (7.27 vs. 5.03 vs. 9.83 months, respectively; p=0.035), while no significant differences were observed in terms of PFS (2.7 vs. 2.9 vs. 3.1 months, respectively; p=0.740). There was no significant difference in the baseline QoL scores between the three groups (p>0.05); after treatment, life quality in SCA and CON group was significantly better than that in the DOX group (p<0.05). Furthermore, the incidence of adverse events (AEs) in the SCA group was significantly lower (46.00 vs. 79.17 vs. 25.00%, respectively; p=0.038) and the incidence of grade ≥3 AEs was also significantly lower in the SCA group compared with the DOX and CON groups (10.00 vs. 82.00 vs. 30.00%, respectively; p=0.042). Single-agent SCA and single-agent DOX has similar therapeutic efficacy in the second-line treatment of advanced/metastatic NSCLC with wild-type or unknown EGFR status, but single-agent SCA has fewer AEs and better QoL. Also, SCA plus DOX can significantly improve OS and exerted a significant synergistic effect, with good safety and tolerance profile.

show abstract

Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer

Cited by 5 publications

References 27 publications

Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments

Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments

Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma

Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

Contact Info

Product

Resources

About